EpiAge Research Publication Signals a New Era in Understanding Biological Aging

January 11, 2025

FOR IMMEDIATE RELEASE

Singapore – January 9, 2025 – EpiMedTech Global, a leader in genetic and epigenetic innovation, is excited to share a major milestone in biological age research: the publication of its study detailing the proprietary EpiAge algorithm. This research, now featured in the peer-reviewed journal Aging Albany, reveals the science behind EpiAge—a revolutionary tool that redefines how we measure biological age with precision and simplicity.

EpiAge has been commercially available since 2019, empowering health-conscious individuals and professionals to assess biological age. The newly published study validates the algorithm through data from over 4,600 participants, proving its accuracy and reliability across diverse samples, including non-invasive saliva testing.

Key Features of EpiAge

Scientific Openness: For the first time, EpiAge’s algorithm and validation details are fully disclosed, reflecting EpiMedTech’s commitment to advancing transparency in epigenetics.
Efficient and Cost-Effective: By analyzing just one region within the ELOVL2 gene, EpiAge achieves accuracy while reducing complexity and cost compared to other models.
Wide-Ranging Applications: From studying Alzheimer’s disease to monitoring the effects of stress, EpiAge has proven effective in detecting age-related changes across various health conditions.
Convenience Redefined: With accurate results from both blood and saliva samples, EpiAge offers a non-invasive alternative, making testing more accessible to users everywhere.

“This moment represents a turning point—not just for our company, but for the field of epigenetic research,” said Professor Moshe Szyf, Founder and CEO of EpiMedTech Global. “EpiAge is more than an algorithm; it’s a bridge to understanding how our bodies age and what we can do to address it. By sharing this research, we’re helping to unlock new possibilities in personalized health and longevity.”

EpiAge continues to be an important tool for researchers and clinicians worldwide, enabling deeper insights into the molecular mechanics of aging. We are eager to further partner with clinicians to explore incorporation of the EpiAge test in clinical practice. The publication of this study underscores its pivotal role in advancing science and improving lives.

For the full study and further information, visit this link.